ABOUT US
Driving Access Through Decision-Ready Evidence (WHY)
We improve patient access by converting fragmented data into decision-ready insights that reflect how payers and HTA bodies in MENA and the GCC make reimbursement decisions.
Our integrated approach reduces uncertain
accelerates approval timelines, and enables predictable, sustainable access for high-value therapies in resource constrained health systems
Health Economics, HTA & Market Access Expertise (WHA)
We deliver locally grounded HTA, HEOR, real-world evidence, advanced analytics, pricing, and managed entry solutions aligned with national guidelines and payer expectations. Through rigorous analytics and structured value frameworks, we develop credible dossiers and access strategies that directly support reimbursement, pricing, a post-launch decision-making.
Strategic Health Consulting & System Transformation (HOW)
Beyond individual products, we work with pharmaceutical companies and public health institutions to address system-level access and HTA gaps. From readiness assessment to capability building and policy execution, we support the transition toward mature, value-based decision frameworks with lasting system impact.
OUR CUSTOMERS
"Medical Consultation; and Health Technology Assessment ” is the main driven key word
Health Economics & Real-World Evidence
Assessment of costs, outcomes, and value to inform efficient healthcare decision-making.
Market Access
Strategic planning to secure timely patient access through Regulatory & Payers alignment.
Reimbursement Strategy
Designing evidence-based pathways for pricing, coverage, and sustainable funding approval.
HTA Advisory
Expert guidance to navigate HTA requirements, submissions, and value demonstration.
Have questions?
Get in touch!
Health Technology Assessment (HTA) & Dossier Development
Regional Market Gap
HTA frameworks are still emerging across the region, with limited institutional capacity, governance frameworks, and consistent procedures for HTA implementation in MENA/GCC. Governments are actively building capacity, but HTA remains nascent in many countries.
Added Value of Addressing the Gap
Establishing standardized, locally framed HTA and dossier development processes accelerates evidence-based pricing and reimbursement decisions, reducing approval uncertainty and improving resource allocation.
Health Economics & Outcomes Research (HEOR)
Regional Market Gap
There is a shortage of local effectiveness data and unit cost information needed for economic evaluations in GCC countries, which hinders generation of credible HEOR evidence relevant for regional HTA and payer decisions.
Added Value of Addressing the Gap
Strengthening HEOR with locally relevant data and economic models increases payer confidence in cost-effectiveness and budget impact conclusions, improving chances of positive reimbursement outcomes.
Advanced Modeling & Decision Analytics
Regional Market Gap
Use of sophisticated decision-analytic methods (e.g., advanced simulations and multi-criteria assessment) is limited in the region; most health economic evaluations remain simplistic and poorly equipped to reflect real clinical and budget uncertainties.
Added Value of Addressing the Gap
Applying robust modeling and analytics tailored to regional payer priorities supports transparent, risk-sensitive decisions (e.g., value beyond cost per QALY) and enhances negotiation power with HTA bodies.
Data Analytics & Real-World Evidence (RWE)
Regional Market Gap
Real-world evidence infrastructure (linked data systems and real-world datasets) is underdeveloped, creating challenges in conducting credible RWE studies for economic evaluation and post-launch evidence generation.
Added Value of Addressing the Gap
Developing RWE capabilities enables ongoing performance tracking and strengthens long-term evidence plans, reducing payer uncertainty and supporting performance-based agreements.
Market Access Strategy & Pricing
Regional Market Gap
Access strategies in MENA/GCC often lack integration with local policy landscapes and payer evidence needs, resulting in delayed or unpredictable pricing approvals and sub-optimal access pathways.
Added Value of Addressing the Gap
Designing market access strategies fully aligned with national HEOR, HTA, and pricing frameworks improves predictability, shortens time to market, and strengthens negotiation positions.
Managed Entry Agreements (MEAs) & Risk-Sharing Models
Regional Market Gap
Despite growing interest, MEAs (e.g., outcome-based agreements) and risk-sharing solutions remain underutilized and lack practical implementation frameworks in many GCC systems.
Added Value of Addressing the Gap
Operational MEA frameworks tied to real outcomes reduce payer risk exposure, foster shared accountability, and expand access to high-value therapies that might otherwise face rejection under traditional pricing models.
Medical & Scientific Evidence Services
Regional Market Gap
Clinical evidence synthesis in the region often lacks multi-dimensional assessments (economic, clinical, ethical) tailored to local decision-making needs; HTA quality reviews show gaps in comprehensive reporting in similar emerging contexts.
Added Value of Addressing the Gap
Delivering evidence packages that integrate clinical, economic, and ethical dimensions enhances credibility and alignment with payer requirements, improving reimbursement success rates.
Market Intelligence & Health Policy Analysis
Regional Market Gap
Rapidly evolving health systems (e.g., new HTA units, universal health coverage reforms) require up-to-date policy intelligence, yet systematic monitoring and localized insights remain limited.
Added Value of Addressing the Gap
Providing timely, localized policy and competitive intelligence enables proactive planning and reduces strategic risk in access and pricing decisions.
Global-to-Local Adaptation Services
Regional Market Gap
Global evidence packages are frequently insufficient for local decision contexts due to unique regulatory, epidemiological, and budgetary conditions in GCC/MENA.
Added Value of Addressing the Gap
Adapting evidence to reflect regional epidemiology, cost structures, and practice patterns improves local credibility and acceptance of value propositions.
Global-to-Local Adaptation Services
Regional Market Gap
Global evidence packages are frequently insufficient for local decision contexts due to unique regulatory, epidemiological, and budgetary conditions in GCC/MENA.
Added Value of Addressing the Gap
Adapting evidence to reflect regional epidemiology, cost structures, and practice patterns improves local credibility and acceptance of value propositions.
Patient Support Programs (PSP)
Regional Market Gap
PSPs in the region are often underdeveloped or disconnected from payer evidence needs, limiting their impact on adherence and long-term outcomes data generation.
Added Value of Addressing the Gap
PSPs that integrate with HEOR and access strategies improve patient adherence, generate real-world outcomes, and strengthen payer confidence for ongoing access.
Stakeholder Engagement & Capacity Building
Regional Market Gap
Limited structured engagement between researchers, policymakers, and payers leads to misalignment and mistrust in evidence generation efforts.
Added Value of Addressing the Gap
Robust public health evidence supports better priority setting, resource planning, and HTA decisions, contributing to sustainable, value-based health systems.
Public Health Studies
Regional Market Gap
Population-level epidemiology and burden studies are relatively limited, which constrains effective prioritization for resource allocation and policy-level HTA decisions in the region.
Added Value of Addressing the Gap
Strategic, consistent stakeholder engagements build collaborative channels that align evidence development with policy priorities and improve uptake of value arguments.